Literature DB >> 21782418

Health-related quality of life (HRQoL) after multimodal treatment for primarily non-resectable rectal cancer. Long-term results from a phase III study.

Morten Brændengen1, Kjell M Tveit, Marianne J Hjermstad, Hemming Johansson, Åke Berglund, Yvonne Brandberg, Bengt Glimelius.   

Abstract

BACKGROUND: A randomised study in non-resectable rectal cancer showed that preoperative chemoradiotherapy (CRT) resulted in better local control and disease-specific survival, but not overall survival than radiotherapy alone. The present paper presents long-term (>4 years) health-related quality of life (HRQoL) and a comparison between the results and reference values from the Norwegian general population.
MATERIAL AND METHODS: A total of 207 patients with primarily non-resectable rectal cancer were randomised to preoperative CRT (2Gyx25+5FU/leucovorin) or RT (2Gyx25) before surgery. HRQoL was assessed using EORTC QLQ-C30, completed at baseline and sent to all patients alive in Norway and Sweden (n=105) after a minimum of 4 years post treatment. A difference of ≥5 points on the 0-100 scales was considered clinically significant.
RESULTS: Seventy-six (72%) patients answered at follow-up. No statistically significant differences between the CRT and RT groups appeared at follow-up, although clinically significant differences in social functioning, dyspnoea and diarrhoea were found. Over time, a clinically significant reduction in physical functioning was found in both groups. Moreover, reduced social functioning and less diarrhoea in the CRT group and better role functioning and more diarrhoea in the RT group were found. Comparisons between the study group and age and gender matched reference values indicate impaired social functioning and more diarrhoea among the patients.
CONCLUSION: There were no statistically significant differences in HRQoL between the randomisation groups. In general, despite having impaired social functioning and more diarrhoea, patients reported HRQoL comparable with the reference population several years after treatment.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21782418     DOI: 10.1016/j.ejca.2011.06.035

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Influence of position and radiation technique on organs at risk in radiotherapy of rectal cancer.

Authors:  Jun-Feng Wang; Hui Li; Hua Xiong; He Huang; Yan-Mei Zou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-10-18

Review 2.  Neo-adjuvant radiotherapy in rectal cancer.

Authors:  Bengt Glimelius
Journal:  World J Gastroenterol       Date:  2013-12-14       Impact factor: 5.742

3.  The association of bowel function, participation in life activities, and quality of life in rectal cancer survivors.

Authors:  Joanna E Bulkley; Carmit K McMullen; Andreea M Rawlings; Robert S Krouse; Melanie C Francisco; Andrew T Sterrett; Andrea N Burnett-Hartman; Pamala A Pawloski; Douglas A Corley; Janice C Colwell; Heather Spencer Feigelson
Journal:  Qual Life Res       Date:  2021-07-12       Impact factor: 4.147

4.  Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future.

Authors:  Bengt Glimelius
Journal:  Ups J Med Sci       Date:  2012-05       Impact factor: 2.384

5.  Organ preservation following short-course radiotherapy for rectal cancer.

Authors:  Per J Nilsson; Madelene Ahlberg; Shahrzad Kordnejad; Torbjörn Holm; Anna Martling
Journal:  BJS Open       Date:  2021-09-06

6.  Effectiveness of radiotherapy for local control in T3N0 rectal cancer managed with total mesorectal excision: a meta-analysis.

Authors:  Michael Jonathan Kucharczyk; Andrew Bang; Michael C Tjong; Stefania Papatheodorou; Jesus C Fabregas
Journal:  Oncotarget       Date:  2022-10-08

7.  Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation.

Authors:  Clemens C Stoffregen; Elisabeth A Odin; Göran U Carlsson; Göran K Kurlberg; Hillevi G Björkqvist; Maria T Tångefjord; Bengt G Gustavsson
Journal:  Anticancer Drugs       Date:  2016-06       Impact factor: 2.248

8.  A randomized study of the effect of patient positioning on setup reproducibility and dose distribution to organs at risk in radiotherapy of rectal cancer patients.

Authors:  Trude C Frøseth; Trond Strickert; Kjersti S Solli; Øyvind Salvesen; Gunilla Frykholm; Randi J Reidunsdatter
Journal:  Radiat Oncol       Date:  2015-10-27       Impact factor: 3.481

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.